Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EuBiologics is a South Korean biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company is a leading global supplier of oral cholera vaccines, including Euvichol and Euvichol-Plus, which are prequalified by the World Health Organization and distributed via UNICEF. EuBiologics utilizes its proprietary EuVCT (Vaccine Conjugation Technology) and EuIMT (Immune Modulator Technology) platforms to develop a robust pipeline, including candidates for typhoid, meningococcal meningitis, COVID-19, and RSV. In addition to its internal R&D, the company operates large-scale manufacturing facilities in Chuncheon and provides CDMO services for biological products. EuBiologics maintains strategic collaborations with international organizations such as the Bill & Melinda Gates Foundation and the International Vaccine Institute to address global health challenges.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Euv Biologics.